Nicholas Vogelzang, MD, FASCO, FACP, regarding sipuleucel-T in mCRPC
Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, offers opinion on when sipuleucel-T should be used in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC)
Tian Zhang, MD, on whether patients in the 1st line setting should receive a single agent TKI
Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, offers opinion on whether patients in the first line setting should receive a single agent TKI
Nicholas Vogelzang, MD, FASCO, FACP, elaborates on combining checkpoint inhibitors in mCRPC
Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, elaborates on combining checkpoint inhibitors with PARP inhibitors, chemotherapy, and anti-hormone agents in metastatic castration-resistant prostate cancer (mCRPC)
Michael Atkins, MD, regarding single agent TKIs in the 1st line setting
Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, considers whether patients in the first line setting may receive a single agent TKI
Nicholas Vogelzang, MD, FASCO, FACP, regarding combination pembrolizumab and olaparib in mCRPC
Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, considers combination pembrolizumab and olaparib and what primary endpoints should look like in these first line metastatic castration-resistant prostate cancer (mCRPC) trials
Tian Zhang, MD, explains how to treat mRCC after combination I-O in the 1st line setting
Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, explains how to treat metastatic renal cell carcinoma (mRCC) after combination I-O in the 1st line setting
Nicholas Vogelzang, MD, FASCO, FACP, offers his impression of KEYNOTE 365 in mCRPC
Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, tell us about the results of KEYNOTE 365 investigating the use of pembrolizumab combined with olaparib in metastatic castration-resistant prostate cancer (mCRPC)
Michael Atkins, MD, considers how to treat mRCC after combination I-O in the 1st line setting
Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, explains how to treat metastatic renal cell carcinoma (mRCC) patients who progress after combination I-O in the first line setting
Nicholas Vogelzang, MD, FASCO, FACP, regarding the evolution of ADT in prostate cancer
Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, elaborates on how androgen deprivation therapy (ADT) is changing for men with newly diagnosed metastatic hormone therapy naïve prostate cancer
Tian Zhang, MD, discusses intermediate/poor and favorable risk RCC patients
Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, explains how we may treat intermediate/poor risk renal cell cancer (RCC) patients versus those that are favorable risk in the first line setting
Michael Atkins, MD, considers intermediate/poor & favorable risk RCC patients
Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, explains how we might treat intermediate/poor risk renal cell cancer (RCC) patients versus those that are favorable risk
Nicholas Vogelzang, MD, FASCO, FACP, on the evolving treatment landscape of nmCRPC
Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, describes the scope of unmet need for non-metastatic castrate-resistant prostate cancer (nmCRPC) patients and how the treatment landscape is evolving
Tian Zhang, MD, elaborates on the outcomes of KEYNOTE 426 presented at GU 2019
Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, shares outcomes from the KEYNOTE 426 Phase III study investigating pembrolizumab in combination with axitinib versus standard of care sunitinib as first line therapy for metastatic renal cell carcinoma (mRCC)
Evan Yu, MD, considers when sipuleucel-T should be used in treatment of mCRPC
Dr. Yu, Professor, Department of Medicine, Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Institute, describes when sipuleucel-T should be used in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC)
Tian Zhang, MD, on predictive biomarkers in selecting patient populations for I-O treatment in RCC
Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, discusses relevant predictors of outcomes for immunotherapy treatment in metastatic renal cell carcinoma (RCC)
Evan Yu, MD, on combining checkpoint inhibitors in metastatic castration-resistant prostate cancer
Dr. Yu, Professor, Department of Medicine, Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Institute, on whether he is concerned combining checkpoint inhibitors with PARP inhibitors, chemotherapy, and anti-hormone agents in metastatic castration-resistant prostate cancer (mCRPC)
Sumit K. Subudhi, MD, PhD, discusses combining checkpoint inhibitors in mCRPC
Dr. Subudhi, Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, on whether or not he is concerned about combining checkpoint inhibitors with PARP inhibitors, chemotherapy, and anti-hormone agents in metastatic castration-resistant prostate cancer (mCRPC)
Evan Yu, MD, regarding combination pembrolizumab and olaparib in mCRPC
Dr. Yu, Professor, Department of Medicine, Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Institute, considers combination pembrolizumab and olaparib and what primary endpoints should look like in these first line metastatic castration-resistant prostate cancer (mCRPC) trials
Sumit K. Subudhi, MD, PhD, on when sipuleucel-T should be used in treatment of mCRPC
Dr. Subudhi, Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, considers when sipuleucel-T should be used in the treatment of metastatic castration-resistant prostate cancer (mCRPC)
Evan Yu, MD, elaborates on the results from KEYNOTE 365 in mCRPC
Dr. Yu, Professor, Department of Medicine, Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Institute, tells us about KEYNOTE 365 investigating the use of pembrolizumab combined with olaparib in metastatic castration-resistant prostate cancer (mCRPC)
Bridget F. Koontz, MD, speculates on the evolving landscape of prostate cancer
Dr. Koontz, Associate Professor of Radiation Oncology, Duke University School of Medicine, offers a radiation oncologist's perspective on the evolving landscape of metastatic prostate cancer
Sumit K. Subudhi, MD, PhD, considers the outcomes of the KEYNOTE 365 study
Dr. Subudhi, Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, tells us about the results of KEYNOTE 365 investigating the use of pembrolizumab combined with olaparib in metastatic castration-resistant prostate cancer (mCRPC)
Bridget F. Koontz, MD, regarding new guidelines on hypofractionated EBRT in prostate cancer
Dr. Koontz, Associate Professor of Radiation Oncology, Duke University School of Medicine, considers key takeaways from the new guidelines on the use of hypofractionated EBRT in localized prostate cancer
Tomasz Beer, MD, regarding the ARAMIS study in nmCRPC from GU 2019
Dr. Beer, Professor of Medicine, Division of Hematology/Medical Oncology, Oregon Health Sciences University, provides his impression of the ARAMIS study investigating the use of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC) from GU 2019
Bridget F. Koontz, MD, on moderate hypofractionation & ultra-hypofractionation in prostate cancer
Dr. Koontz, Associate Professor of Radiation Oncology, Duke University School of Medicine, explains how to differentiate between moderate hypofractionation and ultra-hypofractionation as treatment techniques in localized prostate cancer
Tomasz Beer, MD, elaborates on recent data utilizing LuPSMA in men with mCRPC
Dr. Beer, Professor of Medicine, Division of Hematology/Medical Oncology, Oregon Health Sciences University, shares outcomes from a study presented at GU 2019 using a tumor-specific radioligand – LuPSMA – in men with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on standard therapies.
Rana McKay, MD, explains how to differentiate between TKIs available for renal cell cancer patients
Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, describes how to differentiate between the various TKIs available for renal cell cancer (RCC) patients
Rana McKay, MD, on next steps when treating mRCC patients who receive I-O in the front line space
Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, considers how to treat patients with metastatic renal cell carcinoma (mRCC) who may be treated with combination I-O in the front line setting
William Oh, MD, discusses the evolving treatment landscape for patients with nmCRPC
Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, elaborates on the scope of unmet need for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and how the treatment landscape is evolving
Rana McKay, MD, offers impressions of the TIVO-3 study in highly refractory advanced RCC patients
Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, shares thoughts on the outcomes from the TIVO-3 study investigating tivozanib in highly refractory advanced renal cell carcinoma (RCC)
William Oh, MD, tells us how PSA is valuable as a biomarker in the treatment of prostate cancer
Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, considers how prostate-specific antigen (PSA) is most valuable as a biomarker in the treatment of prostate cancer
Rana McKay, MD, on recent data examining atezolizumab and bevacizumab in nccRCC & sccRCC
Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, offers opinion on whether the results of a GU 2019 Phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC) are practice changing
William Oh, MD, discusses recent data examining LuPSMA in men with mCRPC
Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, shares outcomes of the study presented at the 2019 Genitourinary Cancers Symposium using a tumor-specific radioligand - LuPSMA – in men with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on standard therapies
Rana McKay, MD, considers the implications of CHECKMATE 214 & KEYNOTE-426 presented at GU 2019
Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, on whether the results of KEYNOTE-426 and CHECKMATE 214 influence how we treat intermediate/poor risk renal cell cancer (RCC) patients versus those that are favorable risk in the first line setting
William Oh, MD, regarding data on racial differences in response to novel prostate cancer therapies
Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, summarizes the large retrospective trial presented the 2019 Genitourinary Cancers Symposium demonstrating that African-American men may respond well to newer prostate cancer therapies
Rana McKay, MD, elaborates on the outcomes of the KEYNOTE 426 Phase III study in mRCC
Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, shares outcomes of the KEYNOTE 426 Phase III study investigating pembrolizumab combined with axitinib versus standard of care sunitinib as first line therapy for metastatic renal cell carcinoma (mRCC)
Yair Lotan, MD, considers the role of checkpoint inhibitors in bladder cancer
Dr. Lotan, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, explains how checkpoint inhibition is being incorporated into muscle-invasive and non-muscle-invasive bladder cancer treatment algorithms and whether it appears to combine well with chemotherapy
Yair Lotan, MD, shares outcomes of KEYNOTE 057 in high-risk non-muscle-invasive bladder cancer
Dr. Lotan, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, elaborates on outcomes from the KEYNOTE 057 trial investigating pembrolizumab in patients with high-risk non-muscle-invasive bladder cancer unresponsive to BCG
Mark T. Fleming, MD, regarding the implications of the CHECKMATE 650 study presented at GU 2019
Dr. Fleming, Medical Oncology, Medical Director, Genitourinary Program, US Oncology, Virginia Oncology Associates, tells us about the results of CHECKMATE 650 and the potential to use immune checkpoint inhibitor combinations to treat metastatic castration-resistant prostate cancer (mCRPC)
Yair Lotan, MD, on the challenges using biomarkers for treatment selection in bladder cancer
Dr. Lotan, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, discusses some of the present challenges with using biomarkers for treatment selection in muscle-invasive and non-muscle-invasive bladder cancer
Mark T. Fleming, MD, regarding the Aramis study in prostate cancer
Dr. Fleming, Medical Oncology, Medical Director, Genitourinary Program, US Oncology, Virginia Oncology Associates, provides his opinion on the Aramis study investigating the use of darolutamide in nonmetastatic castration-resistant prostate cancer
Yair Lotan, MD, on molecular characterization & subtyping data in bladder cancer
Dr. Lotan, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, explains how molecular characterization and bladder subtyping data can be used to improve outcomes
Mark T. Fleming, MD, offers his impression of the LATITUDE study in NDx-HR mCNPC
Dr. Fleming, Medical Oncology, Medical Director, Genitourinary Program, US Oncology, Virginia Oncology Associates, regarding the final analysis of the LATITUDE trial investigating abiraterone added to ADT in newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC)
Yair Lotan, MD, considers the latest in screening for high-risk asymptomatic bladder cancer
Dr. Lotan, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, tells us the latest in terms of screening for high-risk asymptomatic bladder cancer
Mark T. Fleming, MD, on the ARCHES trial in metastatic hormone-sensitive prostate cancer
Dr. Fleming, Medical Oncology, Medical Director, Genitourinary Program, US Oncology, Virginia Oncology Associates, regarding outcomes from the ARCHES trial presented at the 2019 Genitourinary Cancers Symposium investigating androgen deprivation therapy (ADT) with enzalutamide or placebo in metastatic hormone-sensitive prostate cancer (mHSPC)
Andrew Armstrong, MD, offers opinion on androgen receptor inhibitors
Dr. Armstrong, Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, elaborates on his experience with androgen receptor inhibitors and how they may impact bone scans
Michael Atkins, MD, offers opinion on IO-TKI combinations in renal cell cancer
Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, discusses combining checkpoint inhibition or any I-O with TKIs in renal cell cancer patients
Andrew Armstrong, MD, discusses the Phase 2 STREAM study in pre-metastatic prostate cancer
Dr. Armstrong, Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, regarding the outcomes of the Phase 2 STREAM study investigating enzalutamide plus salvage radiation plus androgen deprivation therapy (ADT) in men with pre-metastatic prostate cancer
Michael Atkins, MD, regarding the KEYNOTE 426 Phase III trial in metastatic renal cell carcinoma
Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, shares thoughts on the KEYNOTE 426 Phase III study investigating pembrolizumab combined with axitinib versus standard of care sunitinib as first line therapy for metastatic renal cell carcinoma (mRCC)
Andrew Armstrong, MD, presents an overview of the ARCHES trial in mHSPC
Dr. Armstrong, Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, shares results from the ARCHES trial presented at the 2019 Genitourinary Cancers Symposium investigating androgen deprivation therapy (ADT) with enzalutamide or placebo in metastatic hormone-sensitive prostate cancer (mHSPC)
